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and model 1 + initiating-service groups (model 3). Optimism-corrected C-statistics 
and root mean square error (RMSE) were used to compare model prediction accu-
racy. Results: The cohort consisted of 3,105 individuals; of which 38.3% had a 
recurrent episode, with an average cost of $3,803CAD (SD= $11,959). LCA identified 
two groups: high user (15.2%) and low user (84.8%), while about 51.6% of the cohort 
was grouped as institutionalized. Model 2 predicted time to a subsequent episode 
better (C-statistic = 0.94) than model 3 (C-statistic = 0.91), and model 1 (C-statistic 
= 0.87). Model 3 predicted cost of the subsequent episode better (RMSE= 11934.5) 
than model 2 (RMSE= 11999.8) and model 1 (RMSE= 12075.3). ConClusions: The 
findings suggest that both LCA-defined groups and initiating-service groups could 
be used to summarize past utilization for risk prediction modeling; the choice may 
depend on the outcome of interest.
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NoN-DiscRetioNaRy iNPuts aRe iMPoRtaNt FactoRs iN HosPital 
eFFicieNcy stuDies aND Policy evaluatioN
Pasupathy K., Sir M.
Mayo Clinic, Rochester, MN, USA
objeCtives: Hospital efficiency is the focus of several studies and increasingly, 
data envelopment analysis (DEA) is used to compute and compare efficiencies of 
hospitals for quality improvement and policy analysis. DEA is a non-parametric 
approach to compute efficiency considering multiple inputs and outputs and bench-
mark hospitals, with the presumption that the inefficient hospitals can reduce 
inputs and/or increase outputs to improve their efficiency. Hospitals are complex 
systems and have multiple non-discretionary inputs, such as type of hospital or 
region of location that are not under the control of administration, and hence cannot 
be altered. This study emphasizes the need to consider non-discretionary inputs 
in DEA models. Methods: One year’s worth of Agency for Healthcare Research & 
Quality’s Health Care Utilization Project data was used. Variables included full-time 
equivalent of registered nurses, licensed practical nurses and nurse aides as inputs 
and total discharges and percent of surgeries as outputs, with bed size, urban/
rural, teaching status, region and ownership as non-discretionary inputs. First a 
variable-returns-to-scale DEA model was run without the non-discretionary inputs. 
Next the model was repeated including an environmental harshness (created using 
regression). Results: When the efficiency scores of the 862 hospitals in the two 
stages were compared, 755 hospitals had increased efficiency, and mean increased 
more than three times from 0.11 (P< 0.000) and standard deviation doubled from 
0.15. The number of efficient hospitals increased from 12 to 72. ConClusions: 
DEA can be a sophisticated method to measure hospital efficiency. Not accounting 
for non-discretionary inputs can radically alter the efficiency scores and bias study 
results. The first stage score has inefficiency and the effect of non-discretionary 
inputs. Since both mean and standard deviation increased dramatically, simple nor-
malization cannot be used as a proxy. Appropriate treatment of non-discretionary 
inputs is necessary to make meaningful comparisons to inform quality and policy 
interventions.
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iMPact oF siNgle Risk FactoR cHaNges oN loNg-teRM outcoMes aND 
cost iN a tyPe 2 Diabetes MoDeliNg stuDy coNtRastiNg PRojectioNs 
WitH ukPDs68, sWeDisH NatioNal Diabetes RegistRy aND tHe aDvaNce 
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objeCtives: Previous studies have investigated changes in risk factor (RF) variables 
on cost and outcomes in the IMS-CORE-Diabetes-Model (CDM) using UKPDS-68 
(UK-68-RE) and UKPDS-82 risk equations (UK-82-RE). The objective of this study 
was to project health benefits and total lifetime costs (TLC) associated with a range 
of selected RF changes utilizing UK-68-RE versus recently implemented RE within 
the CDM: the Swedish-National-Diabetes-Registry (S-NDR) and the ADVANCE-
Risk-Engine (ARE). Methods: The CDM was applied to project the lifetime ben-
efits (life years (LYs), quality adjusted life years (QALYs)) and TLC ($US) associated 
with baseline RF changes for HbA1c (+/-1%), body-mass-index (BMI) (+/-1 Kg/m2), 
systolic-blood-pressure (SBP) (+/-20 mmHg), total-cholesterol (TC) (+/-10 mg/dl), 
(high-density-lipoprotein (HDL) (+/-5 mg/dl) and low-density-lipoprotein (LDL) (+/-
10 mg/dl). An intermediate risk type-2 diabetes cohort (age 52 years, HbA1c 8%, SBP 
140 mm-Hg, BMI 30 Kg/m2, HDL 50 mg/dl and LDL 150 mg/dl) was projected over 
lifetime to explore the sensitivity of discounted (3%) LYs, QALYs and TLC per unit RF 
variation. Results: When UK-68-RE were applied, projected changes in LYs were: 
0.096, 0.045, 0.013, 0.071, -0.183 and 0.0 and QALYS: 0.156, 0.067, 0.065, 0.051, -0.121 
and 0.0 for RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. This 
compared to changes of 0.103, 0.032, 0.004, 0.070, -0.195, 0.044 (LYs) and 0.150, 0.049, 
0.054, 0.050, -0.132, 0.025 (QALYs) utilizing S-NDR-RE and 0.103, 0.030, 0.001, 0.065, 
-0.093, 0.0 (LYs) and 0.163, 0.057, 0.056, 0.048, -0.062, 0.0 (QALYs) utilizing ARE-RE. 
TLC decreased by $3’479, $1’065, $69, -$414, $1’263, $0, (UK-68-RE); $2’829, $852, $81, 
-$289, $910, -$347 (S-NDR-RE ) and $3’488, $1’196, -$10, -$182, $694, $0 (ARE-RE) for 
RF variations in HbA1c, SBP, BMI, TC, HDL and LDL, respectively. ConClusions: 
The degree to which RF changes are translated into benefits and costs may change 
considerably dependent on the choice of selected risk equations.
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objeCtives: To investigate the costs associated with the management of patients 
who sought emergency care due to DRMs. Methods: This study was a retrospec-
tive analysis of patients’ medical records. 535 patients sought emergency services 
over a six-month period in a large teaching hospital in Brazil and those with DRM 
situation 3; CIs cannot defined), the combination of the two proposed methods 
produces CIs as single range. ConClusions: We reviewed the issues related to 
using the conventional methods to calculate ICER CIs, and proposed new methods 
to address these. Proposed methods yield CIs that can be more easily interpreted. 
However, some issues remain that require further discussion.
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MetHoDology usiNg PHaRMacy aND MeDical claiMs Data to evaluate 
Real-WoRlD outcoMes aND costs oF ivF tReatMeNt iN tHe us
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objeCtives: To describe the methodology used to identify treatment cycles and 
determine real-world outcomes associated with the in vitro fertilization (IVF) treat-
ments, follicle-stimulating hormone (FSH) versus FSH+human menopausal gonado-
tropin (hMG), using administrative claims data. Methods: This retrospective study 
used the Truven Healthcare MarketScan® Claims Database to identify and compare 
IVF treatment protocols, pregnancy and birth outcomes among women aged 18–< 35 
undergoing IVF between January 2009 and December 2012. Patients with ≥ 1 claim for 
a gonadotropin-releasing hormone agonist (GnRHAg) or antagonist (GnRHAnt) (first 
claim being the index date), ≥ 1 claim for FSH and ≥ 1 claim for human chorionic gon-
adotropin (hCG), using National Drug Codes, were selected. Patients were included 
on identification of a prescription for FSH in the 7 days pre-index through 60 days 
post-index, hCG in the 60 days post-index and ≥ 1 embryo transfer (ET) code (using 
current procedural terminology) ≤ 60 days post-index. The FSH+hMG cohort also 
required identification of ≥ 1 claim for hMG ≤ 60 days post-index. Patient eligibility 
was defined as continuous enrollment for 12 months prior and 18 months post-
index. ICD-9-CM codes were used to identify live birth outcomes within 42 weeks 
of ET. Results: Inclusion/exclusion criteria identified 627 and 852 patients in the 
FSH and FSH+hMG cohorts, respectively. The 18-month post-index eligibility criteria 
accounted for a large number of patients removed (n= 7366). No differences in first-
cycle outcomes were seen between FSH and FSH+hMG for: live birth per ET (38.1% 
vs 38.5%; OR 1.02 [95%CI: 0.82–1.26], p= 0.871) and live birth per pregnancy (54.44% 
vs 54.37%; OR 1.00 [95%CI: 0.78–1.28], p= 0.98), respectively. ConClusions: Most 
published analyses of fertility treatment outcomes are derived from single fertility 
center datasets. This methodology successfully identified two distinct IVF treatment 
protocols and allowed comparison of outcomes using real-world healthcare claims 
data sourced from a variety of fertility centers.
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objeCtives: Kidney disease is a common condition in which kidneys fail to func-
tion properly. In this study, the highest incidence and prevalence rates of end-
stage renal disease [ESRD] (i.e.,both renal transplant and dialysis) were reported 
from the USA, Taiwan, and Japan. In the Arab countries of the Middle East, Saudi 
Arabia recorded the highest prevalence of patients with renal failure of 600 cases 
per million of population, while Kuwait recorded the lowest prevalence rate of 
80 cases per million. In the West Bank, the total number of renal failure patients 
was 692 in the first quarter of 2012—an increase of 11.3% over the same period in 
2011. Methods: Prospective estimates and elicited expert opinions are used to esti-
mate the unit costs of hemodialysis and / or kidney transplantation in the Palestine. 
Our study retrospectively reviewed epidemiological data on hemodialysis including: 
1. Number of patients receiving hemodialysis; 2. Incidence rate; 3. Total mortality. 
The direct cost of kidney transplantation was estimated by dividing the procedures 
into three phases: (1) pre-transplant, (2) transplant, and (3) post-transplant. Cost 
analysis for hemodialysis was performed for each patient on dialysis. Results: 
The average cost for kidney transplant was US$16,277 for the first year; the esti-
mated cost of a single hemodialysis session was US$97; while the cost of hemo-
dialysis per patient was variable, it averaged $16,085 per year—nearly as much 
as a transplant. ConClusions: While live, related kidney donors are scarce, our 
study revealed that kidney transplant was more adequate and less expensive than 
hemodialysis. These results were similar to many related studies, and have direct 
resource allocation implications for government-funded kidney disease services 
funded by through Palestinian Ministry of Health.
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assessiNg tHe iNcReMeNtal PReDictive value oF HealtHcaRe 
utilizatioN PatHWays iN Risk PReDictioN MoDeliNg
Kuwornu J.P.1, Lix L.1, Quail J.2, Wang E.2, Osman M.2, Teare G.2
1University of Manitoba, Winnipeg, MB, Canada, 2Saskatchewan Health Quality Council, 
Saskatoon, SK, Canada
objeCtives: The study objective was to compare the incremental predictive value 
of a probability-based classification versus a deterministic grouping of previous 
healthcare use for subsequent healthcare outcomes. Methods: Administrative 
databases from Saskatchewan, Canada (population 1.1 million) were used to identify 
an incident chronic obstructive pulmonary disease (COPD) cohort (35+ years). All 
episodes of healthcare use for COPD exacerbations between 2007/08 and 2011/2012 
fiscal years were identified. Latent class analysis (LCA) probabilistically grouped the 
cohort based on healthcare utilization in the index episode using visits to general 
practitioners (GP), specialists, emergency departments (ED), inpatient hospitaliza-
tions (IH), and outpatient medication dispensations. Individuals were also deter-
ministically grouped as institutionalized (IH/ED) or ambulatory (GP/specialist) based 
on the initiating service of the index episode. Time to a subsequent episode and 
the cost of the subsequent episode were modelled with Cox proportional hazard 
regression and generalized linear models, respectively; using only demographic 
and disease characteristics (model 1), model 1 + LCA-defined groups (model 2), 
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valiDity oF MeDicaiD aNalytic extRact (Max)-2009, outPatieNt (ot) 
aND PRoviDeR cHaRacteRistics (Pc) Data FoR use iN MeNtal HealtH 
ReseaRcH
Medhekar R., Chen H.
University of Houston, Houston, TX, USA
objeCtives: To assess the validity of Medicaid Analytic Extract (MAX)-2009, 
Outpatient (OT) and Provider Characteristics (PC) data for use in mental health 
research. Methods: Medicaid issue briefs, Medicaid managed-care enrollment 
report, MAX-PC evaluation reports and MAX-validation tables for the year 2009 were 
reviewed to assess the validity of MAX-OT and MAX-PC data. Validity of the data was 
defined in terms of availability [OT: substantial number of encounter claims; PC: 
substantial number of OT billing/servicing provider IDs], completeness [OT: number 
of claims per PME, % enrollees with encounter record, number of claims per service 
user; PC: % provider IDs with primary taxonomy code] and usability [OT: primary 
diagnoses and/or procedure code reported per record]. Each state was ranked on 
these criteria as 1: Good, 2: Fair and 3: Poor for both OT and PC data and a total 
combined-score was calculated. The states with minimum total combined-score, 
which met all the criteria, were considered appropriate for research. Results: 
Thirty-six states delivered some/all mental health services through managed care 
organizations (MCOs) and the rest relied on fee-for-service (FFS). Eleven states con-
tracting with comprehensive MCOs, 4 states contracting with behavioral health 
organizations (BHOs), and 6 FFS states have usable OT-encounter data. PC data was 
available for all 51 states, of which 15 states have usable data with > 90% claims 
with OT billing/servicing provider IDs. Twelve of these states have data with ≥ 75% 
provider IDs with primary taxonomy codes. Three comprehensive MCO states (KY, 
NJ, NY), 2 BHO states (AZ, FL) and 2 FFS states (MS, LA) met all the validity criteria 
for OT and PC files. ConClusions: Although, most states provide mental health 
services through comprehensive MCOs, OT-encounter data for these services is 
usable for limited states only. Researchers should exercise caution while combining 
OT and PC files for mental health research.
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DeveloPMeNt oF a Database oF PublisHeD RegulatoRy 
RecoMMeNDatioNs coNceRNiNg tHe use oF cliNical outcoMe 
assessMeNt (coas) iN DRug DeveloPMeNt: outcoMes iNsite
Perret C.1, Roborel de Climens A.2
1Mapi Research Trust, Lyon, France, 2Mapi, Lyon, France
objeCtives: As defined by the FDA, a Clinical Outcome Assessment (COA) directly 
or indirectly measures how patients feel or function and can be used to determine 
whether or not a drug has demonstrated to provide a treatment benefit. There are 
four types of COAs: patient-reported (PRO), observer-reported (ObsRO), clinician-
reported (ClinRO), and performance outcomes (PerfO). The aim of this research is 
to create an online database of published regulatory recommendations concerning 
the use of COAs to determine treatment benefit and to inform drug approval and 
health technology assessment (HTA) review. Methods: All clinical guidelines pub-
lished from 1977 to 2014 by North American regulatory authorities (FDA and Health 
Canada), the European Union (EMA), and NICE, were retrieved on the corresponding 
websites and reviewed. The information was categorized as follows: guideline title, 
date of publication, guideline status (“draft” or “final/adopted”), therapeutic area and 
indication based on ICD -10 classification, guideline purpose(s), and for each COA, 
the concept of interest and context of use (e.g., targeted patient population, endpoint 
positioning and study design). Results: For the EMA, we reviewed 110 scientific 
guidelines representing 62 therapeutic indications, of which approximately more 
than half recommend COA endpoints. For the FDA, we analyzed 86 guidance repre-
senting 56 therapeutic indications, of which almost 60% recommend COA endpoints. 
For Health Canada, five guidance representing five therapeutic indications were 
retrieved. The 96 recommendations published by the NICE correspond to 75 thera-
peutic indications, and are currently under review. ConClusions: This project will 
be a unique source of centralized information about how COAs are recommended 
by regulatory authorities in drug development and HTA review. It will be useful to 
observe the current trends in COAs recommended, and to integrate them as early 
as possible in the product development. The database will be available online in an 
independent website, with access by subscription.
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a viRtual Database to MeasuRe costs associateD WitH coMoRbiDities 
aMoNg PatieNts WitH cHRoNic Hcv
Kawabata H.1, Behl A.1, Hines P.1, Liu T.1, Sill B.1, Hede S.1, Gorsh B.1, Moorthy V.2
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objeCtives: Healthcare resource utilization and costs are often measured by ret-
rospective claims analyses. Using a common data model (CDM) with standardized 
variables has the ability to enhance robustness and generalizability of data and 
improve the timeliness of these studies. Given the rapidly changing treatment land-
scape for HCV, it is a prime candidate for research based on a CDM. The purpose of 
this study was to analyze healthcare resource use and costs by comorbidity status 
in patients with chronic HCV using a virtual database based on a CDM. Methods: A 
virtual database was created with 3 large commercially available datasources using 
specifications developed by Observational Medical Outcomes Partnership (OMOP) 
CDM v4 format (www.omop.org/CDM). By employing a massively parallel processing 
(MPP) database platform we created this database with 30+ standardized variables 
as needed for this study. Utilizing this virtual database allowed for comparison of 
demographic, clinical, and healthcare utilization variables analyzed simultaneously 
across the large databases for patients with HCV. Results: Results from two of the 
databases (1 commercial/Medicare, 1 commercial only) representing more than 
212,000,000 covered lives yielded information for 97,935 patients with chronic HCV 
(n= 46,384 for database 1; n= 51,551 for database 2). Baseline demographics were 
similar between the databases. Slightly less than 10% of patients had compensated 
cirrhosis, approximately 5% had decompensated cirrhosis, and transplant percent-
were identified using a validated questionnaire. The direct medical costs of patient 
management were estimated using a micro-costing analysis, and a sensitivity analy-
sis conducted using the emergency room visits rates due to DRM reported in the 
literature. All costs are presented in 2014 US$ (US$1= R$2.70). Results: 14.6% of 
patients sought emergency care due to DRM; 58.9% of DRMs were considered pre-
ventable. Mean treatment costs were US$812.38 ± 1,417 (range US$16.04 to 9,832). 
Mean inpatient length of stay of DRM patients was (5.7 ± 8.4 days). An extrapolation 
based on all 57.106 emergency visits in the last year resulted in annual total treat-
ment costs of US$6.773 million. A sensitivity analysis resulted in US$1.043 million 
in the best-case scenario and US$12.989 milion at worst, per year. ConClusions: 
This is one of the first analyses of the economic consequences of DRM in Brazil, and 
shows that DRMs leading to emergency visit and hospital admission are common 
and constitute a significant economic impact to the hospital. Efforts are necessary 
to improve pharmacotherapy and reduce preventable iatrogenic costs.
ReseaRcH oN MetHoDs – Databases & Management Methods
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is tHe PRevaleNce oF alzHeiMeR’s Disease uNDeRestiMateD? 
coMPaRisoNs aND coNtRasts oF DiFFeReNt aPPRoacHes iN estiMatiNg 
alzHeiMeR’s Disease
Yuan J., Lu K.
University of South Carolina, Columbia, SC, USA
objeCtives: Estimating the prevalence of Alzheimer’s disease (AD) has been a chal-
lenge because it has been relying on self/proxy-reported information or based on 
diagnosis alone, yielding inconsistent and underestimated results in the published 
studies. The objective of this study was to provide a more accurate prevalence of AD, 
and to make comparisons and contrast of different approaches in ascertain demen-
tia. Methods: A cross-sectional study was performed using the Medicare Current 
Beneficiary Survey (MCBS) 2010. The study sample consisted of Medicare beneficiar-
ies aged 65 or older. AD was ascertained by using self/proxy’s report, ICD-9-CM diag-
nosis codes in the Medicare claims; AD-targeted prescription medications identified 
from both self/proxy’s report and pharmacy claims, or using a combined sources 
of information. Prevalence was estimated using ross-sectional weights. Weighted 
Kappa coefficients were estimated. Results: The prevalence of AD varied greatly 
by using different sources of information. The prevalence of AD was dropped from 
6.8% when using a combined methodology, to 3.5% when using self/proxy’s report 
alone, 1.4% when using claims data alone, and 5.3% when based on the utilization of 
AD-target medications. Using data from AD-target medications (78%) captured more 
AD cases than using self-reported data alone (52%) and claims only (21%), which 
was observed in both community and long-term care facilities. These discrepancies 
in describing AD cases were significant. The agreement between AD-target medica-
tions and claims data was 30.7% (kappa= 0.28), 38.4% between AD-target medications 
and self/proxy’s report (kappa= 0.49), and 47.2% between self/proxy-reported and 
AD-target medications (kappa= 0.27).Compared to pharmacy claims, self-reported 
medication use provided slightly higher estimates of AD cases (48.5% vs. 40.8%; 
kappa= 0.26). ConClusions: The prevalence of AD was largely underestimated by 
using self/proxy’s report or claims alone. Our findings have important implications 
for identifying AD cases, and suggested a better algorism of capturing AD. Further 
research is warranted to validate the algorisms to identify AD cases.
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uNiFieD Database cReatioN aPPlieD to Public bRaziliaN HealtH 
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iNFoRMatioN systeMs
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objeCtives: Unify and deterministically deduplicate databases’ of patients regis-
tration information coming from Information Systems of SUS in Brazil: Hospital, 
Output and Mortality Information Systems, between the years 2000-2012, to get 
an individualize data and plot patients’ lines of care during the period, enabling 
pharmacoeconomic and epidemiological studies that parameterize effectiveness 
and efficiency of public policies and embedded technologies. Methods: Semantic 
analysis of data was performed to describe and understand different meanings 
of different fields existing in the studied bases. In addition, there were two main 
procedures, executed with database operations tools and PLSQL programming lan-
guage: cleaning and standardization of databases; registration information extrac-
tion and deterministic deduplication thereof. Both procedures were first performed 
on each database separately and after the unification of the records, was held again 
a deterministic deduplication. Results: Performed procedures allowed a decision-
making to chose fields used in data model for the unified database creation. Five 
database’s representative fields related to patients were selected: first name and 
last name; birth date; state and country code of residence. Initially, the unified 
cadastral database resulted in 570,649,706 records, after deduplication there was a 
reduction culminating in 106,433,845 records. This reduction is explained because 
these databases are not fully integrated. Moreover, there is not always agreement 
between semantic systems and in some cases changes occur in the data format 
over the period within the same system. ConClusions: The results show that 
data deduplication is necessary and should be carried out thoroughly. Where the 
databases had limited patients’ registration information, the technique enabled to 
capture, in more complete basis, additional information. Futhermore, it allowed to 
identify and assist in the understanding of positive and negative aspects within 
systems and trace clinical condition of patients, enabling pharmacoeconomic and 
epidemiological studies that define effectiveness and efficiency of public policies 
and embedded technologies. As future work, is important ensure the univocity of 
records.
